Postes actifs de Roland Muduryan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
HepGene, Inc.
 HepGene, Inc. BiotechnologyHealth Technology HepGene, Inc. operates as a biotechnology firm. The company was founded in 2020 and is headquartered in Fairfield, CT. | Directeur/Membre du Conseil | - | - |
Mammogen, Inc.
 Mammogen, Inc. BiotechnologyHealth Technology Mammogen, Inc. is a female-led biotechnology company that focuses on improving the detection, diagnosis, and treatment of women's health-related diseases. Mammogen is based in Aliso Viejo, CA and was founded by Martin J. Keiser. The private company's proprietary gentrutm liquid biopsy platform, which leverages novel messenger RNA technology, is used in its flagship gentru-breasttm program to non-invasively detect and diagnose breast cancer. Mammogen's multi-gene expression signature for breast cancer detection has been extensively validated in blood and saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. The company's product pipeline consists of an array of non-invasive prognostics and diagnostics for additional diseases that affect some-, mostly-, or only-women. Elizabeth Cormier-May has been the CEO of the company since 2021. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Roland Muduryan
Statistiques
Internationale
| Etats-Unis | 3 |
Opérationnelle
| Director/Board Member | 2 |
Sectorielle
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
HepGene, Inc.
HepGene, Inc. BiotechnologyHealth Technology HepGene, Inc. operates as a biotechnology firm. The company was founded in 2020 and is headquartered in Fairfield, CT. | Health Technology |
Mammogen, Inc.
Mammogen, Inc. BiotechnologyHealth Technology Mammogen, Inc. is a female-led biotechnology company that focuses on improving the detection, diagnosis, and treatment of women's health-related diseases. Mammogen is based in Aliso Viejo, CA and was founded by Martin J. Keiser. The private company's proprietary gentrutm liquid biopsy platform, which leverages novel messenger RNA technology, is used in its flagship gentru-breasttm program to non-invasively detect and diagnose breast cancer. Mammogen's multi-gene expression signature for breast cancer detection has been extensively validated in blood and saliva, and has shown statistical significance towards providing measurable improvement upon current standards of care. The company's product pipeline consists of an array of non-invasive prognostics and diagnostics for additional diseases that affect some-, mostly-, or only-women. Elizabeth Cormier-May has been the CEO of the company since 2021. | Health Technology |
- Bourse
- Insiders
- Roland Muduryan
- Expérience
